• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

    8.900 +0.250 (+2.89%)
    Streaming Delayed Price Updated: 3:57 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CNS Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 Next >
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
    Via Investor Brand Network
    12 Health Care Stocks Moving In Monday's After-Market Session
    Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over... 
    Via Benzinga
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
    Via Investor Brand Network
    Study Suggests That Test of Memory May Signal Brain Tumor Presence
    Via Investor Brand Network
    Symptoms of Brain Tumors To Watch For
    Via Investor Brand Network
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
    Via Investor Brand Network
    Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
    Via Investor Brand Network
    Topics Death
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
    Via Investor Brand Network
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
    Via Investor Brand Network
    Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
    Via Investor Brand Network
    Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
    Via Investor Brand Network
    Topics Death
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
    Via Investor Brand Network
    Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
    Via Investor Brand Network
    Study Finds That Ketogenic Diet May Help Patients with Brain Cancer
    Via Investor Brand Network
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
    Via Investor Brand Network
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
    Via Investor Brand Network
    Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
    Via Investor Brand Network
    Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
    Via Investor Brand Network
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment
    Via Investor Brand Network
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    AI May Help Improve Brain Cancer Diagnosis
    Via Investor Brand Network
    Topics Artificial Intelligence
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval for Protocol Amendment to Ongoing Potentially Pivotal Berubicin Trial
    Via Investor Brand Network
    44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
    Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering. 
    Via Benzinga
    Study Suggests Healthcare Workers Don’t Know Enough About Childhood Brain Tumors
    Via Investor Brand Network
    Study Finds That Brain Tumors May Originate from Different Site
    Via Investor Brand Network
    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.